Application of milrinone in preparation of medicine for treating diabetic foot ulcer

A technology for diabetic foot ulcers and milrinone, which is applied in the fields of biotechnology and medicine, can solve the problems of few short-term follow-up studies of patients with DFD or DFU, ulcer recurrence, and the risk of re-amputation

Inactive Publication Date: 2013-10-30
RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After conservative or surgical treatment and discharge, DFU patients still face many problems with poor prognosis, such as poor healing of foot ulcers, ulcer recurrence, risk of re-amputation, cardiovascular and cerebrovascular events, and death. The existence of these problems greatly threatens foot ulcers. Patient recovery and survival
After conservative or surgical treatment and discharge, DFD patients still face many problems with poor prognosis, such as poor healing of foot ulcers, ulcer recurrence, risk of re-amputation, occurrence of cardiovascular and cerebrovascular events, and death. Patient recovery and survival
[0007] At present, domestic and foreign studies on DFU mostly focus on the follow-up of amputation and survival of patients, or the study of long-term survival, recurrence of foot ulcers, and amputation. However, there are relatively few reports on short-term series follow-up of patients with DFD or DFU.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of milrinone in preparation of medicine for treating diabetic foot ulcer
  • Application of milrinone in preparation of medicine for treating diabetic foot ulcer
  • Application of milrinone in preparation of medicine for treating diabetic foot ulcer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] The selection of embodiment 1 research object

[0024] Inclusion criteria: patients with type 1 or type 2 diabetes, meeting the WHO definition of diabetic foot disease, that is, diabetic patients with lower extremity infection, ulceration and / or destruction of deep tissues due to neuropathy and various degrees of peripheral vascular disease ; DFU patients with Wagner grade 1-5; meet the Framingham diagnostic criteria for heart failure, and NYHA grade Ⅱ-Ⅲ; blood pressure ≥ 90 / 60mmHg.

[0025] The severity of DFD is graded using the Wagner grading method, and the specific grades are as follows: grade 0, skin intact (before ulceration), with peripheral vascular disease and high-risk signs of the foot; grade 1, skin surface ulcers, subcutaneous Within the fat layer; Grade 2, ulcer depth reaches tendons or ligaments; Grade 3, osteomyelitis or extensive infection of deep tissues; Grade 4, gangrene of the toes or front of the foot; Grade 5, gangrene of the entire or involving ...

Embodiment 2

[0036] Embodiment 2 Administration

[0037] Using a randomized, controlled, single-blind method, the DFU patients included in the study were randomly divided into an intensive treatment group and a conventional treatment group according to different treatment schemes. A total of 142 patients with DFU combined with heart failure were included in the study, including 67 cases in the intensive treatment group, 65 cases were completed, 1 case was lost to follow-up, and 1 case was withdrawn from the study due to drug intolerance; 75 cases were in the conventional treatment group, 72 cases were completed, and 3 cases were lost to follow-up. example. There was no significant difference in the number of cases lost to follow-up between the two groups (P>0.05).

[0038] Conventional treatment group: conventional treatment, that is, according to the guidelines for the diagnosis and treatment of heart failure proposed by AHA, losartan potassium (50 mg, orally, once a day) was given to di...

Embodiment 3

[0044] There are 3 time nodes in the study: baseline period, 2 weeks and 3 months of treatment.

[0045] Statistical methods: Statistical processing was carried out using the Microsoft Windows version of SAS9.13 statistical software package. The measurement data satisfying the normal distribution is expressed by x±s, the comparison between two groups is performed by t test, and the comparison between multiple groups is performed by analysis of variance, while the measurement data of non-normal distribution is expressed by M(P25, P75), and logarithmic transformation is used Then compare between groups. The count data are expressed as ratios, and the four tables and the x of R×C are used 2 The test was compared with Fisher's exact test. All tests were two-sided, and P<0.05 was defined as statistically significant.

[0046] By monitoring the changes of ankle-brachial index (ABI) in patients with foot ulcers before and after treatment, it was observed whether the intensive trea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine and biotechnology, and particularly relates to application of a medicine. Milrinone is used for preparing the medicine for treating or improving diabetic foot ulcer or diabetic foot ulcer combined with heart failure. The invention provides the new application of the milrinone for preparing the medicine, and provides a new thinking and a method for preparing the medicine for treating the diabetic foot ulcer or diabetes combined with heart failure. The milrinone can effectively improve the therapeutic effect of diabetic foot ulcer and the quality of life of a patient, and provides a basis for clinical treatment for treating and intensifying heart failure and promoting foot ulcer healing.

Description

technical field [0001] The invention relates to the fields of biotechnology and medicine, in particular to the medical application of milrinone. Background technique [0002] Diabetic foot disease (DFD) is one of the serious complications of advanced diabetes. According to the definition of WHO, DFD refers to lower extremity infection, ulceration and / or destruction of deep tissues in diabetic patients due to neuropathy and various degrees of peripheral vascular disease; the basic pathogenic factors of DFD include neuropathy, ischemia And biomechanical changes, these factors together lead to tissue infection, ulceration and gangrene. [0003] The severity of DFD is graded using the Wagner grading method, and the specific grades are as follows: grade 0, skin intact (before ulceration), with peripheral vascular disease and high-risk signs of the foot; grade 1, skin surface ulcers, subcutaneous Within the fat layer; Grade 2, ulcer depth reaches tendons or ligaments; Grade 3, o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/444A61P3/10A61P17/02A61P9/04
Inventor 宁光钱泓洁汤正义
Owner RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap